The analysis of the cardiovascular system medicine sales in Germany, expressed in value, shows a gradual increase over the years. In 2023, the sales stood at 4.95 billion Euros. From 2019 to 2023, the compound annual growth rate (CAGR) was 1.74%, indicating steady growth. The year-on-year variation over the last two years showed minimal increases of 0.46% in 2022 and 0.44% in 2023. Looking forward, from 2024 to 2028, the forecasted 5-year CAGR is expected to slow down to 0.3%, projecting moderate growth.
Future trends to watch:
- Technological advancements in cardiovascular treatments.
- Increasing prevalence of cardiovascular diseases.
- Rising healthcare expenditures in Germany.
- Regulatory changes impacting pharmaceutical pricing.
- Emergence of new market players and innovative therapies.
